LONDON, UK, and SAN DIEGO, USA – May 30, 2014 – Gensignia Ltd, a London-based privately held microRNA company, has appointed Lee McCracken as Chief Executive Officer of its wholly owned subsidiary, Gensignia Life Sciences, Inc. Mr McCracken will lead San Diego based Gensignia Life Sciences, Inc. to advance the company’s unique “Dx/Rx” business model in oncology, with an initial focus on launching the company’s molecular diagnostic test for early detection of lung cancer.
Mr McCracken has more than 20 years’ experience in the pharmaceutical, biotechnology, diagnostics and venture capital industries. He recently served as President and CEO of Pathwork Diagnostics. Pathwork developed and commercialized an FDA-cleared molecular diagnostic for cancer, with Medicare and private payer reimbursement, and was sold to Response Genetics in 2013.
Previously, Mr McCracken held senior corporate roles at Prometheus Laboratories, Diversa, GenStar Therapeutics, CombiChem and Allergan. Mr McCracken began his career in venture capital at Union Venture before joining 3i Capital.
Mr McCracken holds a BS in Commerce / Marketing from Santa Clara University, a Master of Computer Science from University of Dayton and an MBA in Strategy / Venture Capital from the Anderson School of Management at UCLA.
Gabriele Cerrone, Founder and Executive Chairman of Gensignia Ltd, said: “Lee brings considerable commercial, strategic development, and international experience to Gensignia at an important time in our development. Striking results for our microRNA Signature Classifier (MSC) lung cancer assay were published this past January in the Journal of Clinical Oncology and we now look forward to progressing to a commercial launch in the United States and in key international markets.”
Commenting on his appointment, Lee McCracken said: “I am delighted to join Gensignia at an exciting time in its development and I look forward to working with the London, Milan, and San Diego teams in advancing our microRNA business to help patients around the world, initially by making a massive impact on lung cancer diagnosis and treatment.”
Gensignia Ltd is a London-based privately held microRNA company with its founding research team in Milan, Italy and a wholly owned San Diego based subsidiary, Gensignia Life Sciences, Inc. With its laboratory operations in San Diego, Gensignia is pursuing a unique “Dx/Rx” business model in oncology. Gensignia is developing proprietary molecular diagnostic blood tests designed to provide more accurate detection of cancer as well as developing complementary therapeutics. In 2015, Gensignia intends to introduce a lung cancer diagnostic test in the US.
Statements in this press release about the Company’s expectations, applications of its technology, markets, launch of tests and other statements that are not historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s current beliefs, assumptions, estimates and projections. Actual results could differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience and dependence on key personnel and financing.
Phil Boyd, Chief Financial Officer
020 3727 1000